Rhythm Biosciences Limited (ASX:RHY)

Market Cap	17.04M
Revenue (ttm)	3.17M
Net Income (ttm)	-2.18M
Shares Out	284.08M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,439
Average Volume	210,637
Open	0.0580
Previous Close	0.0600
Day's Range	0.0580 - 0.0610
52-Week Range	0.0420 - 0.1400
Beta	2.10
RSI	44.03
Earnings Date	May 21, 2025

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In 2024, Rhythm Biosciences's revenue was 1.69 million, a decrease of -45.41% compared to the previous year's 3.10 million. Losses were -6.86 million, -16.56% less than in 2023.